More 2 Marketing Podcast

The episode is dominated by a lengthy founder origin story with only a handful of non-obvious marketing observations (direct-to-corporate CPG, unexpected truck driver market, MVP testing in the workplace). The host's lengthy closing summary repeats these same points verbatim with no added substance, and most advice reduces to 'use your network' and 'pivot when it works.'

“don't be afraid to pivot and if it's working great, throw your business plan in the bin and just start doing the thing that's working”

“no one had gone direct to corporates before. So that was amazing. Um, surprised me how well it worked”

The angle on FMCG ingredient under-dosing as an industry-wide fraud is genuinely interesting and not often discussed, and the return-and-earn scheme critique has a contrarian edge. However, the overarching marketing framework ('know your audience, use your network, test your MVP') is entirely conventional and the episode doesn't produce any first-principles thinking about B2B marketing.

“the nutrition industry in Australia is rife with ridiculously under dosed products that do not work at the dose which the ingredients are in there, they're sub therapeutic”

“a lot of manufacturers and other people tend to do is they put in a tiny percentage of what you actually need to get the benefit”

Mark Curry is a genuine operator who bootstrapped a physical product from $17k and no manufacturing relationships to 1,000+ stores - real practitioner credibility. However, the business remains modest in scale, and his insights are almost entirely specific to early-stage Australian FMCG/CPG, limiting relevance for most B2B operators in other domains.

“we're now at over a thousand stores”

“the most awarded, uh, nutrition company in Australia at the moment”

There are genuinely specific data points scattered throughout - 11,000 units sold in five weeks, 512 clinical studies cited, 22 ingredients, 13 - 14 cent per-unit recycling levy, 57% fuel surcharge - and named companies like Coles and Nestle. The specificity mostly serves the origin narrative rather than producing transferable evidence about marketing ROI or channel performance.

“the whole formula is based on 512 clinical pieces of evidence. That's why it took me 18 months to get that first drink bottled”

“I could only afford to make 11,000 drinks. We managed to sell out in five weeks”

The host asks almost exclusively open, validating questions and rarely follows up to probe contradictions or extract specifics. The closing monologue - which runs several minutes and simply restates what the guest said - is a significant drag on substance. There is no productive disagreement or pressure applied at any point.

“No, and it testifies to how different Savvy is in your approach to it. So why don't you tell everyone a bit about you”

“Mark, have I missed anything?”